Platelet, Neutrophil and Lymphocyte Quantitative Abnormalities in Patients with Heart Failure: A Retrospective Study

Figures & data

Table 1 Socio-Demographic and Clinical Characteristics of the Heart Failure Patients at the University of Gondar Comprehensive Specialized Hospital, 2022

Variables	Categories	Frequency (N)	Percentage (%)
Gender	Male	93	38.0
	Female	152	62.0
Residence	Urban	145	59.2
	Rural	100	40.8
Age (Years)	18–25	18	7.3
	26–35	20	8.2
	36–45	22	9.0
	46–55	41	16.7
	≥56	144	58.8
Duration since heart failure diagnosis (years)	≤3	180	73.5
	>3	65	26.5
Etiology of heart failure	CRVHD	48	19.6
	IHD	100	40.8
	HHD	81	33.1
	DVHD	70	28.6
NYHA functional class	Class I	21	8.6
	Class II	115	46.9
	Class III	40	16.3
	Class IV	69	28.2

Abbreviations: CRVHD, Chronic valvular heart disease; IHD, Ischemic heart disease; HHD, Hypertensive heart disease; DVHD, degenerative valvular heart disease; NYHA, New York Heart Association.

Figure 1 Common comorbidity among patients with heart failure at the University of Gondar comprehensive specialized hospital.

Notes: Others* indicate hypothyroidism, generalized tonic-clonic seizures or epilepsy, bronchial asthma, dyslipidemia, and old ischemic stroke.

Figure 2 Major medication received by heart failure patients at the University of Gondar comprehensive specialized hospital.

Table 2 Some Hematogical and Biochemical Parameters of Adults with Heart Failure Attending at the University of Gondar Comprehensive Specialized Hospital

Parameters	Mean ±SD	Minimum	Maximum
Platelet (×10^3/μL)	239.06±91.25	29.0	780.0
Mean platelet volume (fl)	9.22±2.09	4.7	24.8
Neutrophil (×10^3/μL)	5.28±2.64	1.5	20.2
Lymphocyte (×10^3/μL)	2.65±1.67	0.3	16.3
Neutrophil (%)	57.06±15.18	21.0	96.4
Lymphocyte (%)	28.94±14.00	4.8	86.8
FBS (mg/dL)	117.26±36.26	19.0	260.0
Urea (mg/dL)	29.70±18.52	1.3	175.0
Creatinine (mg/dL)	0.78±0.45	0.09	3.42
SGPT (IU/L)	26.72±17.87	2.0	135.0
SGOT (IU/L)	33.22±24.79	5.0	210

Abbreviations: SGPT, serum glutamic pyruvic transaminase; SGOT, serum glutamic-oxaloacetic transaminase; FBS, fasting blood sugar; SD, standard deviation.

Figure 3 Platelet, neutrophil and lymphocyte abnormalities among patients with heart failure attending at the university of Gondar comprehensive specialized hospital.

Table 3 Logistic Regression Analysis of Factors Associated with Neutrophilia Among Patients with Heart Failure at the University of Gondar Comprehensive Specialized Hospital

Variables	Category	Neutrophilia		COR (95% CI)	AOR (95% CI)
		Yes N (%)	No N (%)
Sex	Male	11 (11.83)	82 (88.17)	1	1
	Female	32 (21.05)	120 (78.95)	1.98 (0.94–4.17)	2.33 (1.05–5.16)*
Age (years)	18–35	4(10.53)	34 (89.47)	1	1
	36–50	4(10.53)	39 (90.70)	0.87 (0.20–3.75)	0.60 (0.13–2.78)
	>50	35 (21.34)	129 (78.66)	2.30 (0.77–6.93)	1.84 (0.58–5.84)
Duration since heart failure diagnosis	<3 years	31 (17.22)	149 (82.78)	1	1
	≥3 years	12 (18.40)	53 (81.54)	1.08 (0.52–2.27)	0.82 (0.38-0.79)
Comorbidity	No	1 (6.25)	15 (93.75)	1	1
	Yes	42 (18.34)	187 (81.66)	3.37 (0.43–26.21)	2.67 (0.32–22.18)
SGPT (IU/L)	Normal	19 (14.29)	114 (85.71)	1	1
	Elevated	24 (21.43)	88 (78.57)	1.63 (0.84–3.17)	1.74 (0.81–3.71)
SGOT (IU/L)	Normal	28 (15.91)	148 (84.09)	1	1
	Elevated	15 (21.74)	54 (78.26)	1.47 (0.72–2.95)	1.26 (0.57–2.78)
Creatinine(mg/dl)	Normal	38 (16.59)	191 (83.41)	1	1
	Elevated	5 (31.25)	11 (68.75)	2.28 (0.75–6.95)	2.43 (0.74–7.93)

Notes: 1 indicates reference category, *Indicates statistically significant.

Abbreviations: SGPT, serum glutamic pyruvic transaminase; SGOT, serum glutamic-oxaloacetic transaminase; AOR, adjusted odds ratio; COR, crude odds ratio; CI, confidence interval.